Radius is a science-driven fully integrated biopharmaceutical company that is committed to developing and commercializing innovative endocrine therapeutics in the areas of osteoporosis and oncology. Radius' lead product, TYMLOSÂŽ (abaloparatide) injection was approved by the U.S. Food and Drug Administration for the treatment of postmenopausal women with osteoporosis at high risk for fracture. The Radius clinical pipeline includes investigational abaloparatide injection for potential use in the treatment of men with osteoporosis; an investigational abaloparatide patch for potential use in osteoporosis; the investigational drug elacestrant (RAD1901) for potential use in hormone-receptor positive breast cancer; and the investigational drug RAD140 under investigation for potential use in hormone-receptor positive breast cancer. Source
No articles found.
MYOS RENS Technology, Inc. (NASDAQ: MYOS), a company based in Cedar Knolls, NJ was...
MYOS RENS Technology, Inc. (NASDAQ: MYOS), a co...
Vesper Corporation (Vesper) is a corporation formed under the laws of the State ...
Vesper Corporation (Vesper) is a corporation ...
Armed with cutting-edge technology and MIT science, experienced business and medic...
Armed with cutting-edge technology and MIT scie...
Cortexyme is a biopharmaceutical company developing therapeutics based on data sup...
Cortexyme is a biopharmaceutical company develo...
Oramed Pharmaceuticals (NASDAQ: ORMP) was established in 2006, and has developed a...
Oramed Pharmaceuticals (NASDAQ: ORMP) was estab...
Amphastar Pharmaceuticals, Inc., headquartered in Rancho Cucamonga, California, es...
Amphastar Pharmaceuticals, Inc., headquartered ...
NextCure is a clinical-stage biopharmaceutical company committed to discovering an...
NextCure is a clinical-stage biopharmaceutical ...
Join the National Investor Network and get the latest information with your interests in mind.